Curcumin enhances human macrophage control of Mycobacterium tuberculosis infection

Respirology

Volumn 21, Issue 5, 2016, Pages 951-957

  Bai, Xiyuan ^a,b,c   Oberley Deegan, Rebecca E ^b,e   Bai, An ^a,b   Ovrutsky, Alida R ^b,c   Kinney, William H ^b,c   Weaver, Michael ^b   Zhang, Gong ^d   Honda, Jennifer R ^b,c   Chan, Edward D ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b DEPARTMENT OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d SHAANXI UNIVERSITY OF CHINESE MEDICINE   (China)

^e UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

apoptosis; autophagy; curcumin; nuclear factor kappa B; tuberculosis

Indexed keywords

CASPASE 3; CURCUMIN; CYTOCHROME C; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BAX; TRANSCRIPTION FACTOR RELA;

ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; BACTERIAL CLEARANCE; BACTERIAL GROWTH; BACTERIAL SURVIVAL; CELL COUNT; CONCENTRATION RESPONSE; DRUG EFFICACY; DRUG RESPONSE; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG ALVEOLUS MACROPHAGE; MONOCYTE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; TUBERCULOSIS;

EID: 84975085406     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12762     Document Type: Article

References (45)

1. Gray JM, Cohn DL. Tuberculosis and HIV coinfection. Semin. Respir. Crit. Care Med. 2013; 34: 32–43.
2. Deretic V. Autophagosome and phagosome. Methods Mol. Biol. 2008; 445: 1–10.
3. Fenton MJ. Macrophages and tuberculosis. Curr. Opin. Hematol. 1998; 5: 72–8.
4. Placido R, Mancino G, Amendola A, Mariani F, Vendetti S, Piacentini M, Sanduzzi A, Bocchino ML, Zembala M, Colizzi V. Apoptosis of human monocytes/macrophages in Mycobacterium tuberculosis infection. J. Pathol. 1997; 181: 31–8.
5. Schaible UE, Winau F, Sieling PA, Fischer K, Collins HL, Hagens K, Modlin RL, Brinkmann V, Kaufmann SH. Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis. Nat. Med. 2003; 9: 1039–46.
6. Srinivasan L, Ahlbrand S, Briken V. Interaction of Mycobacterium tuberculosis with host cell death pathways. Cold Spring Harb Perspect Med. 2014; 4: a022459.
7. Briken V, Miller JL. Living on the edge: inhibition of host cell apoptosis by Mycobacterium tuberculosis. Future Microbiol. 2008; 3: 415–22.
8. Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as “Curecumin”: from kitchen to clinic. Biochem. Pharmacol. 2008; 75: 787–809.
9. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003; 23: 363–98.
10. Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 2013; 15: 195–218.
11. Jagetia GC, Aggarwal BB. “Spicing up” of the immune system by curcumin. J. Clin. Immunol. 2007; 27: 19–35.
12. Killian PH, Kronski E, Michalik KM, Barbieri O, Astigiano S, Sommerhoff CP, Pfeffer U, Nerlich AG, Bachmeier BE. Curcumin inhibits prostate cancer metastasis in vivo by targeting the inflammatory cytokines CXCL1 and -2. Carcinogenesis 2012; 33: 2507–19.
13. Sa G, Das T. Anti cancer effects of curcumin: cycle of life and death. Cell Div. 2008; 3: 14.
14. Shehzad A, Park JW, Lee J et al. Curcumin induces radiosensitivity of in vitro and in vivo cancer models by modulating pre-mRNA processing factor 4 (Prp4). Chem. Biol. Interact. 2013; 206: 394–402.
15. Shishodia S, Amin HM, Lai R, Lee YS. Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem. Pharmacol. 2005; 70: 700–13.
16. Singh S, Aggarwal BB. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J. Biol. Chem. 1995; 270: 24995–5000.
17. Wilken R, Veena MS, Wang MB, Srivatsan ES. Curcumin: a review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol. Cancer 2011; 10: 12.
18. Bai X, Feldman NE, Chmura K, Ovrutsky AR, Su WL, Griffin L, Pyeon D, McGibney MT, Strand MJ, Numata M et al. Inhibition of nuclear factor-kappa B activation decreases survival of Mycobacterium tuberculosis in human macrophages. PLoS One 2013; 8: e61925.
19. Bai X, Kim SH, Azam T, McGibney MT, Huang H, Dinarello CA, Chan ED. IL-32 is a host protective cytokine against Mycobacterium tuberculosis in differentiated THP-1 human macrophages. J. Immunol. 2010; 184: 3830–40.
20. Yang CW, Chang CL, Lee HC et al. Curcumin induces the apoptosis of human monocytic leukemia THP-1 cells via the activation of JNK/ERK pathways. BMC Complement. Altern. Med. 2012; 12: 22.
21. Gutierrez MG, Master SS, Singh SB, Chi CW, Pan JP, Yang WC. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell 2004; 119: 753–66.
22. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, Kominami E, Ohsumi Y, Yoshimori T. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 2000; 19: 5720–8.
23. Mizushima N, Yoshimori T, Levine B. Methods in mammalian autophagy research. Cell 2010; 140: 313–26.
24. Chan ED, Morris KR, Belisle JT, Hill P, Remigio LK, Brennan PJ, Riches DW. Induction of inducible nitric oxide synthase-NO* by lipoarabinomannan of Mycobacterium tuberculosis is mediated by MEK1-ERK, MKK7-JNK, and NF-kappaB signaling pathways. Infect. Immun. 2001; 69: 2001–10.
25. Morris KR, Lutz RD, Bai X, McGibney MT, Cook D, Ordway D, Chan ED. Suppression of IFNgamma + mycobacterial lipoarabinomannan-induced NO by IL-4 is due to decreased IRF-1 expression. Tuberculosis (Edinb.) 2009; 89: 294–303.
26. Morris KR, Lutz RD, Choi HS, Kamitani T, Chmura K, Chan ED. Role of the NF-kappaB signaling pathway and kappaB cis-regulatory elements on the IRF-1 and iNOS promoter regions in mycobacterial lipoarabinomannan induction of nitric oxide. Infect. Immun. 2003; 71: 1442–52.
27. Migliori GB, Sotgiu G, Gandhi NR, Falzon D, DeRiemer K, Centis R, Hollm-Delgado MG, Palmero D, Pérez-Guzmán C, Vargas MH et al. The Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur. Respir. J. 2013; 42: 169–79.
28. Chan ED, Strand MJ, Iseman MD. Treatment outcomes in extensively resistant tuberculosis. N. Engl. J. Med. 2008; 359: 657–9.
29. Chan ED, Laurel V, Strand M, Chan JF, Hyunh M-L, Goble M, Iseman MD. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 2004; 169: 1103–9.
30. Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, Leimane V, Andries K, Bakare N, De Marez T et al. TMC207-C208 Study Group. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N. Engl. J. Med. 2014; 371: 723–32.
31. Avorn J. Approval of a tuberculosis drug based on a paradoxical surrogate measure. JAMA 2013; 309: 1349–50.
32. Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, Gao M, Awad M, Park SK, Shim TS et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N. Engl. J. Med. 2012; 366: 2151–60.
33. Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, Pistorius C, Krause R, Bogoshi M, Churchyard G et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N. Engl. J. Med. 2009; 360: 2397–405.
34. Cox E, Laessig K. FDA approval of bedaquiline--the benefit-risk balance for drug-resistant tuberculosis. N. Engl. J. Med. 2014; 371: 689–91.
35. Li MY, Wang HL, Huang J, Shi GC, Wan YG, Wang JX, Xi XE. Curcumin inhibits 19-kDa lipoprotein of Mycobacterium tuberculosis induced macrophage apoptosis via regulation of the JNK pathway. Biochem. Biophys. Res. Commun. 2014; 446: 626–32.
36. Gupta PK, Kulkarni S, Rajan R. Inhibition of intracellular survival of multi drug resistant clinical isolates of Mycobacterium tuberculosis in macrophages by curcumin. Open Antimicrobial Agents J. 2013; 4: 1–5.
37. Changtam C, Hongmanee P, Suksamrarn A. Isoxazole analogs of curcuminoids with highly potent multidrug-resistant antimycobacterial activity. Eur. J. Med. Chem. 2010; 45: 4446–57.
38. Baldwin PR, Reeves AZ, Powell KR, Napier RJ, Swimm AI, Sun A, Giesler K, Bommarius B, Shinnick TM, Snyder JP et al. Monocarbonyl analogs of curcumin inhibit growth of antibiotic sensitive and resistant strains of Mycobacterium tuberculosis. Eur. J. Med. Chem. 2015; 92: 693–9.
39. Guo C, Rosoha E, Lowry MB, Borregaard N, Gombart AF. Curcumin induces human cathelicidin antimicrobial peptide gene expression through a vitamin D receptor-independent pathway. J. Nutr. Biochem. 2013; 24: 754–9.
40. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J, Wu K, Meinken C et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006; 311: 1770–3.
41. Yamada H, Mizuno S, Reza-Gholizadeh M, Sugawara I. Relative importance of NF-kappa B p50 in mycobacterial infection. Infect. Immun. 2001; 69: 7100–5.
42. Jäger R, Lowery RP, Calvanese AV, Joy JM, Purpura M, Wilson JM. Comparative absorption of curcumin formulations. Nutr. J. 2014; 13: 11.
43. Prasad S, Tyagi AK, Aggarwal BB. Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice. Cancer Res Treat. 2014; 46: 2–18.
44. Yadav VR, Prasad S, Kannappan R, Ravindran J, Chaturvedi MM, Vaahtera L, Parkkinen J, Aggarwal BB. Cyclodextrin-complexed curcumin exhibits anti-inflammatory and antiproliferative activities superior to those of curcumin through higher cellular uptake. Biochem. Pharmacol. 2010; 80: 1021–32.
45. Hotchkiss RS, Moldawer LL. Parallels between cancer and infectious disease. N. Engl. J. Med. 2014; 371: 380–3.